PRÉPARED BY: DATE PREPARED: PHONE: Sandy Sostad March 28, 2012 471-0054

LB 882

Revision: 01

## FISCAL NOTE

51161E 1=1 5=5

LEGISLATIVE FISCAL ANALYST ESTIMATE

Revised on 3/28/12 based on amendments adopted through 3/27/12.

-----

ESTIMATE OF FISCAL IMPACT – STATE AGENCIES *						
	FY 2012-13 FY 2013-14					
	EXPENDITURES REVENUE EXPENDITURES			REVENUE		
GENERAL FUNDS						
CASH FUNDS						
FEDERAL FUNDS						
OTHER FUNDS						
TOTAL FUNDS						

\*Does not include any impact on political subdivisions. See narrative for political subdivision estimates.

LB 882 requires health insurance plans sold in the state on or after October 1, 2012 to provide coverage for a prescribed orally administered anticancer medication used to kill or slow the growth of cancerous cells on a basis no less favorable than intravenously administered or injected cancer medications that are covered by the insurance plans. The cost to the covered individual shall not exceed the coinsurance or copayment that would be applied to the other cancer treatment. Language in the bill prohibits a reclassification of any anticancer medication or increase in coinsurance, copayment, deductible or other out- of-pocket expense on any anticancer medication to achieve compliance with the bill. The provisions of the bill terminate on December 31, 2015.

The Department of Administrative Services and the University of Nebraska indicate that health insurance plans offered to state employees currently cover both orally administered anticancer medications and intravenously administered or injected cancer medications, so no fiscal impact is projected for these plans.

The University indicates that the provisions of the bill requiring that any changes increasing out-of-pocket expenses for anticancer medications are to be applied to the majority of comparable medical or pharmaceutical benefits under the plan may be difficult to coordinate between the two vendors (health care & drug) providing health care benefits for University employees.

DEPARTMENT OF ADMINISTRATIVE SERVICES

	REVIEWED BY 1	Gary Bush	1/11/12	PHONE 4/1-2526
COMMENTS				
DEPT. OF INS	URANCE - Concur.			
UNIVERSITY (	OF NEBRSKA – No basis	to disagree with estimate.		
		to along to him community		
DEPT OF ADA	INISRATIVE SERVICES	S – Concur		
DEI I. OI ABI	MINION MINION	o condui.		

## $LB^{\scriptscriptstyle{(1)}}$ 882 FISCAL NOTE

JAN 1 1 2012

State Agency OR Political Subdivision Name: (2)		Department of I	Department of Insurance I EGISTATIVE ETSCAT			
Prepared by: (3)	Eric Dunning	Date Prepared: (4)	1-10-12	Phone: <sup>(5)</sup>	1-4650	
	ESTIMATE PRO	OVIDED BY STATE AGE	NCY OR POLITIC	AL SUBDIVIS	ION	
	FY	7 2012-2013		FY 2013-2	2014	
	EXPENDITUR		EXPENDIT		REVENUE	
GENERAL FUNI	os	<u> </u>				
CASH FUNDS						
FEDERAL FUNI	os					
OTHER FUNDS						
TOTAL FUNDS						
No fiscal impact						
Personal Services		AJOR OBJECTS OF EXP	ENDITURE			
		NUMBER OF POSITION  12-13  13-14	S 2012-20 EXPENDIT		2013-2014 EXPENDITURES	
Benefits			_			
Travel						
Capital outlay			1			
			<del></del>			
	ents			<del></del>		
TOTAL						

Please complete ALL (5) blanks in the first three lines.

JAN 18 2012

### LB<sup>(1)</sup> 882 FISCAL NOTE

State Agency OR Politic	al Subdivision Name: (2)	University of Neb	oraska <u>III</u>	CISLATIVE	TCC.
Prepared by: (3) Mic	hael Justus	Date Prepared: (4)	January 17, 2012	Phone: (5)	402 472 2191
	ESTIMATE PROVID	ED BY STATE AGEN	ICY OR POLITICAL	SUBDIVIS	ION
	FY 201 EXPENDITURES	12-2013 <u>REVENUE</u>	<u>EXPENDITU</u>	FY 2013-2 RES	014 <u>REVENUE</u>
GENERAL FUNDS					
CASH FUNDS					
FEDERAL FUNDS					
OTHER FUNDS				<del></del>	
TOTAL FUNDS					
Return by date specified Explanation of Estima	or 72 hours prior to public te:	hearing, whichever is ear	rlier.		

This bill seems to require that our healthcare plan and drug plan coordinate benefits so that both intravenous and orally administered cancer drugs are on the same footing for costs. The University generally covers both benefits, but the two plans are NOT coordinated. There is no way to estimate the increased costs of administering such an approach, but it would be an increase administrative burden requiring contractual changes with both healthcare and drug plan administrators.

	<u>MAJOR OBJE</u>	<u>CTS OF EXPENI</u>	DITURE	
Personal Services:				
	NUMBER OF	F POSITIONS	2012-2013	2013-2014
POSITION TITLE	<u>12-13</u>	<u>13-14</u>	<b>EXPENDITURES</b>	<b>EXPENDITURES</b>
,				
Benefits				
Operating				
Travel			-	
Capital outlay	••			
Aid				
Capital improvements				
<u> </u>				***************************************
TOTAL	••			

# 2012 Legislative Bill Proposal Fiscal Note

JAN 18 2012

Bill #: 882

**State Agency: Administrative Services** 

Prepared by: Paula Fankhauser

**Date Prepared: 01/11/2012** 

Phone: 402-471-2832

Approved by:

#### Estimate of Fiscal Impact - State Agencies

	FY 2012-13 Expenditures Revenue		FY 2013-14		
			Expenditures	Revenue	
General Funds					
Cash Funds					
Federal Funds					
Other Funds					
Total Funds	0	0	0	0	

#### **Explanation of Estimate:**

LB 882 requires coverage for prescribed, orally administered anticancer medication that is used to kill or slow the growth of cancerous cells on a basis no less favorable than intravenously administered or injected cancer medications that are covered as medical benefits by a plan.

The State employee health plans currently cover both the orally administered drug and the intravenously administered drug. It is up to the physician to determine and prescribe appropriate treatment for any individual patient.

As both are currently covered by the State's health plan there is no fiscal impact to the Department of Administrative Services.

#### **Major Objects of Expenditure**

#### **Personal Services:**

	Number of Positions		2012-13	2013-14	
Position Title:	12-13	13-14	Expenditures	Expenditures	
<del></del>					
, . ,					
Benefits				1	
Operating					
Travel					
Capital Outlay					
Aid					
Capital Improvements					
TOTAL					